On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Earth Science Tech Inc.’s (ETST) Hygee Home Kit Playing Key Role in Fight Against STIs and Undiagnosed Cases

  • ETST’s Hygee(TM) home testing kit for STIs helps women discreetly detect diseases
  • The CDC estimates that there are 20 million new STI cases each year

As sexually transmitted infections (STIs) are reaching epidemic proportions worldwide, especially in remote regions with limited access to health care, men and women are searching for tools to take control of their sexual health. Earth Science Tech Inc. (OTCQB: ETST), a diverse biotech company focused on the nutraceutical and pharmaceutical fields, has developed the revolutionary Hygee(TM) home testing kit that allows women to screen for STIs like chlamydia and gonorrhea from the comfort of their own homes.

STI is an umbrella term encompassing 35 infectious organisms that are transmitted primarily through sexual activity (http://ibn.fm/6AFTz). The Centers for Disease Control and Prevention (CDC) estimates that there are approximately 20 million new STD infections each year. Furthermore, the CDC estimates that undiagnosed and untreated STDs cause infertility in some 24,000 women in the U.S. each year. This creates an unmet demand for a discreet in-home screening tool like Hygee, which looks like – and is worn like – a standard panty liner.

“The best way to fight STIs is prevention, and the only way for women to avoid the dangerous results of untreated STI, is early treatment,” ETST CEO and Chief Science Officer Dr. Michel Aubé stated in a news release (http://ibn.fm/qUHno). “This means that women need to know if they are infected. We believe that Hygee(TM) will be the best tool to provide that information.”

Currently, most cases of STIs remain undiagnosed and untreated, posing a danger to pregnant women and their unborn babies. Results may include infertility in women and blindness or stillborn death in infants (http://ibn.fm/sjvOC). Not only does ETST provide a private screening tool, it also provides access to treatment recommendations through its partner testing lab.

Through Hygee, ETST offers the utmost in privacy for women suspecting that they may have an STI, which could be a key factor in decreasing the number of infections that remain undiagnosed each year. While many women may fear the stigma of being diagnosed with an STI, Hygee addresses that problem. The kit is for home use and conducted anonymously. Results are transferred through the mail, and women can read their lab results in private. By enabling more women around the world to have access to an easy, private screening tool, it may be possible to stem the flood of STIs globally.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

From Our Blog

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Helomics Leverages Cutting-Edge Tech and Datasets to Improve Cancer Outcomes

May 22, 2020

POAI subsidiary Helomics helps oncologists individualize cancer treatment using patient-derived tumor models to improve outcomes Helomics’ tumor genomic and drug response database is one of the largest in the world with over 150,000 tumors across 137 cancer types Expected CAGR of 10.3% from 2018-2024 for oncology segment of precision medicine industry The relationship between a […]

Rotate your device 90° to view site.